Skip to content

Sally Meikle

4 papers in the library · 72 citations · publishing 2019-2025

Papers

Sort Most recent Most cited

Psilocybin with psychotherapeutic support for treatment-resistant depression: a pilot clinical trial

Therapeutic Advances in Psychopharmacology September 1, 2025 Sally Meikle, Olivia Carter, Paul Liknaitzky et al. 2 citations

Background: Depressive disorders are a major global health challenge, with many individuals unresponsive to existing treatments. Novel psychedelic therapies show promise but require further research. Objectives: This study aimed to evaluate the feasibility, safety and effectiveness of psilocybin with psychotherapeutic support for treatment-resistant depression (TRD), investigate predictors of...

Side-effects of mdma-assisted psychotherapy: a systematic review and meta-analysis

Neuropsychopharmacology April 23, 2024 Julia Colcott, Olivia Carter, Sally Meikle et al. 37 citations

Abstract Evidence suggests that MDMA-assisted psychotherapy (MDMA-AP) has therapeutic potential for treatment of psychiatric illness. We conducted the first comprehensive systematic review and meta-analysis of the side effects of MDMA-AP across indications. We also assessed the quality of side effects-reporting in published trials of MDMA-AP. PubMed, EMBASE, PsycINFO, MEDLINE and Cochrane...

Psilocybin-assisted therapy for depression: How do we advance the field?

Australian & New Zealand Journal of Psychiatry November 22, 2019 Sally Meikle, Paul Liknaitzky, Susan L. Rossell et al. 19 citations

In the quest for new treatment options for depression, attention is being paid to the potential role of psychedelic drugs. Psilocybin is of particular interest given its mechanism of action, its benefits in early trials and its relatively low side effects burden. This viewpoint outlines a number of key issues that remain to be elucidated about its potential use in the clinical environment,...